{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:36:06Z","timestamp":1784054166712,"version":"3.55.0"},"publisher-location":"Cham","reference-count":75,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030105600","type":"print"},{"value":"9783030105617","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/164_2018_154","type":"book-chapter","created":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T08:39:16Z","timestamp":1540543156000},"page":"383-410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Designer Benzodiazepines: Another Class of New Psychoactive Substances"],"prefix":"10.1007","author":[{"given":"Bjoern","family":"Moosmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Auw\u00e4rter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,27]]},"reference":[{"key":"154_CR1","doi-asserted-by":"publisher","unstructured":"Ameline A, Richeval C, Gaulier J-M, Raul J-S, Kintz P (2018) Characterization of flunitrazolam, a new designer benzodiazepine, in oral fluid after a controlled single administration. J Anal Toxicol. https:\/\/doi.org\/10.1093\/jat\/bky01","DOI":"10.1093\/jat\/bky01"},{"key":"154_CR2","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1021\/cr60256a004","volume":"68","author":"GA Archer","year":"1968","unstructured":"Archer GA, Sternbach LH (1968) Chemistry of benzodiazepines. Chem Rev 68:747\u2013784","journal-title":"Chem Rev"},{"key":"154_CR3","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/0166-2236(87)90130-5","volume":"10","author":"EA Barnard","year":"1987","unstructured":"Barnard EA, Darlison MG, Seeburg P (1987) Molecular biology of the GABAA receptor: the receptor\/channel superfamily. Trends Neurosci 10:502\u2013509","journal-title":"Trends Neurosci"},{"key":"154_CR4","volume-title":"Disposition of toxic drugs and chemicals in man","author":"RC Baselt","year":"2011","unstructured":"Baselt RC (2011) Disposition of toxic drugs and chemicals in man, 9th edn. Biomedical Publications, Seal Beach","edition":"9"},{"key":"154_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0140-6736(95)91209-6","volume":"346","author":"TM Bauer","year":"1995","unstructured":"Bauer TM, Ritz R, Haberth\u00fcr C, Haefeli W, Scollo-Lavizzari G, Ha H, Hunkeler W, Sleight A (1995) Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 346:145\u2013147","journal-title":"Lancet"},{"key":"154_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/bdd.2510010306","volume":"1","author":"LD Bo","year":"1980","unstructured":"Bo LD, Marcucci F, Mussini E, Perbellini D, Castellani A, Fresia P (1980) Plasma levels of chlorodesmethyldiazepam in humans. Biopharm Drug Dispos 1:123\u2013126","journal-title":"Biopharm Drug Dispos"},{"key":"154_CR7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/pauz.200600216","volume":"36","author":"H B\u00f6nisch","year":"2007","unstructured":"B\u00f6nisch H (2007) Pharmakologie der Benzodiazepine: Allosterische Aktivatoren an GABAA-Rezeptoren. Pharm Unserer Zeit 36:186\u2013194","journal-title":"Pharm Unserer Zeit"},{"key":"154_CR8","doi-asserted-by":"publisher","first-page":"7S","DOI":"10.1111\/j.1365-2125.1979.tb00449.x","volume":"8","author":"DD Breimer","year":"1979","unstructured":"Breimer DD (1979) Pharmacokinetics and metabolism of various benzodiazepines used as hypnotics. Br J Clin Pharmacol 8:7S\u201313S","journal-title":"Br J Clin Pharmacol"},{"key":"154_CR9","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1021\/jm9904349","volume":"43","author":"M Chebib","year":"2000","unstructured":"Chebib M, Johnston GA (2000) GABA-activated ligand gated ion channels: medicinal chemistry and molecular biology. J Med Chem 43:1427\u20131447","journal-title":"J Med Chem"},{"key":"154_CR10","first-page":"7","volume":"65","author":"G Chouinard","year":"2004","unstructured":"Chouinard G (2004) Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry 65:7\u201312","journal-title":"J Clin Psychiatry"},{"key":"154_CR11","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1080\/004982599238056","volume":"29","author":"JK Coller","year":"1999","unstructured":"Coller JK, Somogyi AA, Bochner F (1999) Flunitrazepam oxidative metabolism in human liver microsomes: involvement of CYP2C19 and CYP3A4. Xenobiotica 29:973\u2013986","journal-title":"Xenobiotica"},{"key":"154_CR12","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00414-017-1541-6","volume":"131","author":"S Balkhi El","year":"2017","unstructured":"El Balkhi S, Chaslot M, Picard N, Dulaurent S, Delage M, Mathieu O, Saint-Marcoux F (2017) Characterization and identification of eight designer benzodiazepine metabolites by incubation with human liver microsomes and analysis by a triple quadrupole mass spectrometer. Int J Legal Med 131:979\u2013988","journal-title":"Int J Legal Med"},{"key":"154_CR13","volume-title":"European drug report 2017: trends and developments","author":"EMCDDA","year":"2017","unstructured":"EMCDDA (2017) European drug report 2017: trends and developments. Publications Office of the European Union, Lisbon"},{"key":"154_CR14","unstructured":"EMCDDA (2018) Early warning system alert. Accessible via EDND database of the EMCDDA, Lisbon"},{"key":"154_CR15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00280074","volume":"40","author":"C Fracasso","year":"1991","unstructured":"Fracasso C, Confalonieri S, Garattini S, Caccia S (1991) Single and multiple dose pharmacokinetics of etizolam in healthy subjects. Eur J Clin Pharmacol 40:181\u2013185","journal-title":"Eur J Clin Pharmacol"},{"key":"154_CR16","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1515\/cclm-2016-0831","volume":"55","author":"F Franz","year":"2017","unstructured":"Franz F, Angerer V, Jechle H, Pegoro M, Ertl H, Weinfurtner G, Janele D, Schl\u00f6gl C, Friedl M, Gerl S, Mielke R, Zehnle R, Wagner M, Moosmann B, Auw\u00e4rter V (2017) Immunoassay screening in urine for synthetic cannabinoids \u2013 an evaluation of the diagnostic efficiency. Clin Chem Lab Med 55:1375\u20131384","journal-title":"Clin Chem Lab Med"},{"key":"154_CR17","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/jat\/17.7.427","volume":"17","author":"AD Fraser","year":"1993","unstructured":"Fraser AD, Isner AF, Bryan W (1993) Urinary screening for adinazolam and its major metabolites by the Emit\u00ae d.a.u:\u2122 and FPIA benzodiazepine assays with confirmation by HPLC. J Anal Toxicol 17:427\u2013431","journal-title":"J Anal Toxicol"},{"key":"154_CR18","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0031-6997(24)01424-8","volume":"51","author":"M Gavish","year":"1999","unstructured":"Gavish M, Bachman I, Shoukrun R, Katz Y, Veenman L, Weisinger G, Weizman A (1999) Enigma of the peripheral benzodiazepine receptor. Pharmacol Rev 51:629\u2013650","journal-title":"Pharmacol Rev"},{"key":"154_CR19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11062-014-9429-2","volume":"46","author":"NY Golovenko","year":"2014","unstructured":"Golovenko NY, Larionov V (2014) Pharmacodynamical and neuroreceptor analysis of the permeability of the blood-brain barrier for derivatives of 1,4-benzodiazepine. Neurophysiology 46:199\u2013205","journal-title":"Neurophysiology"},{"key":"154_CR20","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1080\/004982599238173","volume":"29","author":"JC Gorski","year":"1999","unstructured":"Gorski JC, Jones DR, Hamman MA, Wrighton SA, Hall SD (1999) Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily. Xenobiotica 29:931\u2013944","journal-title":"Xenobiotica"},{"key":"154_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2165\/00003088-198106020-00001","volume":"6","author":"D Greenblatt","year":"1981","unstructured":"Greenblatt D (1981) Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet 6:89\u2013105","journal-title":"Clin Pharmacokinet"},{"key":"154_CR22","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/cpt1976203329","volume":"20","author":"DJ Greenblatt","year":"1976","unstructured":"Greenblatt DJ, Schillings RT, Kyriakopoulos AA, Shader RI, Sisenwine SF, Knowles JA, Ruelius HW (1976) Clinical pharmacokinetics of lorazepam. I. Absorption and disposition of oral 14C-lorazepam. Clin Pharmacol Ther 20:329\u2013341","journal-title":"Clin Pharmacol Ther"},{"key":"154_CR23","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1021\/jm00197a021","volume":"22","author":"JB Hester","year":"1979","unstructured":"Hester JB, Von Voigtlander P (1979) 6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity. J Med Chem 22:1390\u20131398","journal-title":"J Med Chem"},{"key":"154_CR24","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1021\/jm00293a015","volume":"14","author":"JB Hester","year":"1971","unstructured":"Hester JB, Rudzik AD, Kamdar BV (1971) 6-Phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines which have central nervous system depressant activity. J Med Chem 14:1078\u20131081","journal-title":"J Med Chem"},{"key":"154_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.forsciint.2016.09.006","volume":"268","author":"G H\u00f8iseth","year":"2016","unstructured":"H\u00f8iseth G, Tuv SS, Karinen R (2016) Blood concentrations of new designer benzodiazepines in forensic cases. Forensic Sci Int 268:35\u201338","journal-title":"Forensic Sci Int"},{"key":"154_CR26","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/BF03189433","volume":"4","author":"M H\u00fcmpel","year":"1979","unstructured":"H\u00fcmpel M, Illi V, Milius W, Wendt H, Kurowski M (1979) The pharmacokinetics and biotransformation of the new benzodiazepine lormetazepam in humans I. Absorption, distribution, elimination and metabolism of lormetazepam-5-14C. Eur J Drug Metab Pharmacokinet 4:237\u2013243","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"154_CR27","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s11419-015-0277-6","volume":"33","author":"L Huppertz","year":"2015","unstructured":"Huppertz L, Bisel P, Westphal F, Franz F, Auw\u00e4rter V, Moosmann B (2015) Characterization of the four designer benzodiazepines clonazolam, deschloroetizolam, flubromazolam, and meclonazepam, and identification of their in vitro metabolites. Forensic Toxicol 33:388\u2013395","journal-title":"Forensic Toxicol"},{"key":"154_CR28","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/dta.2203","volume":"10","author":"LM Huppertz","year":"2018","unstructured":"Huppertz LM, Moosmann B, Auw\u00e4rter V (2018) Flubromazolam \u2013 basic pharmacokinetic evaluation of a highly potent designer benzodiazepine. Drug Test Anal 10:206\u2013211","journal-title":"Drug Test Anal"},{"key":"154_CR29","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/j.1365-2125.2009.03386.x","volume":"67","author":"R Hyland","year":"2009","unstructured":"Hyland R, Osborne T, Payne A, Kempshall S, Logan YR, Ezzeddine K, Jones B (2009) In vitro and in vivo glucuronidation of midazolam in humans. Br J Clin Pharmacol 67:445\u2013454","journal-title":"Br J Clin Pharmacol"},{"key":"154_CR30","first-page":"460","volume":"29","author":"T Kilicarslan","year":"2001","unstructured":"Kilicarslan T, Haining RL, Rettie AE, Busto U, Tyndale RF, Sellers EM (2001) Flunitrazepam metabolism by cytochrome P450s 2C19 and 3A4. Drug Metab Dispos 29:460\u2013465","journal-title":"Drug Metab Dispos"},{"key":"154_CR31","first-page":"57","volume":"29","author":"P Kintz","year":"2017","unstructured":"Kintz P, Jamey C, Ameline A, Richeval C, Raul J-S (2017a) Characterization of metizolam, a designer benzodiazepine, in alternative biological specimens. Toxicol Anal Clin 29:57\u201363","journal-title":"Toxicol Anal Clin"},{"key":"154_CR32","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/dta.2099","volume":"9","author":"P Kintz","year":"2017","unstructured":"Kintz P, Richeval C, Jamey C, Ameline A, Allorge D, Gaulier JM, Raul JS (2017b) Detection of the designer benzodiazepine metizolam in urine and preliminary data on its metabolism. Drug Test Anal 9:1026\u20131033","journal-title":"Drug Test Anal"},{"key":"154_CR33","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3109\/00498257909038746","volume":"9","author":"H Kitagawa","year":"1979","unstructured":"Kitagawa H, Esumi Y, Kurosawa S, Sekine S, Yokoshima T (1979) Metabolism of 8-chloro-6-(o-chlorophenyl)-1-methyl- 4H-s-triazolo [4,3-a] [1,4] benzodiazepine, triazolam, a new central depressant. I. Absorption, distribution and excretion in rats, dogs and monkeys. Xenobiotica 9:415\u2013428","journal-title":"Xenobiotica"},{"key":"154_CR34","volume-title":"Pharmaceutical substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs","author":"A Kleemann","year":"2014","unstructured":"Kleemann A, Engel J, Kutscher B, Reichert D (2014) Pharmaceutical substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs. Thieme, Stuttgart"},{"key":"154_CR35","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/0028-3908(83)90200-9","volume":"22","author":"RA Lahti","year":"1983","unstructured":"Lahti RA, Sethy VH, Barsuhn C, Hester JB (1983) Pharmacological profile of the antidepressant adinazolam, a triazolobenzodiazepine. Neuropharmacology 22:1277\u20131282","journal-title":"Neuropharmacology"},{"key":"154_CR36","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/dta.1981","volume":"9","author":"WJ Lim","year":"2017","unstructured":"Lim WJ, Yap AT, Mangudi M, Koh H, Tang AS, Chan K (2017) Detection of phenazepam in illicitly manufactured Erimin 5 tablets. Drug Test Anal 9:293\u2013305","journal-title":"Drug Test Anal"},{"key":"154_CR37","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3109\/15563650.2015.1112907","volume":"54","author":"M \u0141ukasik-G\u0142\u0119bocka","year":"2016","unstructured":"\u0141ukasik-G\u0142\u0119bocka M, Sommerfeld K, Te\u017cyk A, Zieli\u0144ska-Psuja B, Panie\u0144ski P, \u017baba C (2016) Flubromazolam \u2013 a new life-threatening designer benzodiazepine. Clin Toxicol 54:66\u201368","journal-title":"Clin Toxicol"},{"issue":"8","key":"154_CR38","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/dta.2387","volume":"10","author":"Kieran R. Manchester","year":"2018","unstructured":"Manchester KR, Maskell PD, Waters L (2018) Experimental versus theoretical log D7.4, pKa and plasma protein binding values for benzodiazepines appearing as new psychoactive substances. Drug Test Anal. https:\/\/doi.org\/10.1002\/dta.2387","journal-title":"Drug Testing and Analysis"},{"key":"154_CR39","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.clpt.2004.07.003","volume":"76","author":"AL Masica","year":"2004","unstructured":"Masica AL, Mayo G, Wilkinson GR (2004) In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clin Pharmacol Ther 76:341\u2013349","journal-title":"Clin Pharmacol Ther"},{"key":"154_CR40","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jflm.2011.12.014","volume":"19","author":"PD Maskell","year":"2012","unstructured":"Maskell PD, De Paoli G, Nitin Seetohul L, Pounder DJ (2012) Phenazepam: the drug that came in from the cold. J Forensic Legal Med 19:122\u2013125","journal-title":"J Forensic Legal Med"},{"key":"154_CR41","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00003495-198020050-00002","volume":"20","author":"MAK Mattila","year":"1980","unstructured":"Mattila MAK, Larni HM (1980) Flunitrazepam: a review of its pharmacological properties and therapeutic use. Drugs 20:353\u2013374","journal-title":"Drugs"},{"key":"154_CR42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jchromb.2017.04.008","volume":"1053","author":"L Meng","year":"2017","unstructured":"Meng L, Zhu B, Zheng K, Fu S (2017) Ultrasound-assisted low-density solvent dispersive liquid-liquid microextraction for the determination of 4 designer benzodiazepines in urine samples by gas chromatography-triple quadrupole mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 1053:9\u201315","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"154_CR43","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1007\/s00216-016-9439-6","volume":"408","author":"MR Meyer","year":"2016","unstructured":"Meyer MR, Bergstrand MP, Helander A, Beck O (2016) Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing purposes. Anal Bioanal Chem 408:3571\u20133591","journal-title":"Anal Bioanal Chem"},{"issue":"1","key":"154_CR44","first-page":"008","volume":"1","author":"N Mohsin","year":"2015","unstructured":"Mohsin N, Qadir M (2015) Recent structure activity relationship studies of 1,4-benzodiazepines. Peertechz J Med Chem Res 1(1):008\u20130012","journal-title":"Peertechz J Med Chem Res"},{"key":"154_CR45","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/jms.3279","volume":"48","author":"B Moosmann","year":"2013","unstructured":"Moosmann B, Huppertz LM, Hutter M, Buchwald A, Ferlaino S, Auw\u00e4rter V (2013a) Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics. J Mass Spectrom 48:1150\u20131159","journal-title":"J Mass Spectrom"},{"key":"154_CR46","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s11419-013-0187-4","volume":"31","author":"B Moosmann","year":"2013","unstructured":"Moosmann B, Hutter M, Huppertz L, Ferlaino S, Redlingsh\u00f6fer L, Auw\u00e4rter V (2013b) Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine. Forensic Toxicol 31:263\u2013271","journal-title":"Forensic Toxicol"},{"key":"154_CR47","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/dta.1628","volume":"6","author":"B Moosmann","year":"2014","unstructured":"Moosmann B, Bisel P, Auw\u00e4rter V (2014) Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics. Drug Test Anal 6:757\u2013763","journal-title":"Drug Test Anal"},{"key":"154_CR48","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/wps.20236","volume":"14","author":"B Moosmann","year":"2015","unstructured":"Moosmann B, King LA, Auw\u00e4rter V (2015) Designer benzodiazepines: a new challenge. World Psychiatry 14:248","journal-title":"World Psychiatry"},{"key":"154_CR49","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/jms.3840","volume":"51","author":"B Moosmann","year":"2016","unstructured":"Moosmann B, Bisel P, Franz F, Huppertz LM, Auw\u00e4rter V (2016) Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines \u2013 an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam and nitrazolam. J Mass Spectrom 51:1080\u20131089","journal-title":"J Mass Spectrom"},{"key":"154_CR50","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jpba.2018.02.032","volume":"153","author":"O Mortel\u00e9","year":"2018","unstructured":"Mortel\u00e9 O, Vervliet P, Gys C, Degreef M, Cuykx M, Maudens K, Covaci A, van Nuijs AL, Lai FY (2018) In vitro phase I and phase II metabolism of the new designer benzodiazepine cloniprazepam using liquid chromatography coupled to quadrupole time-of-flight mass spectrometry. J Pharm Biomed Anal 153:158\u2013167","journal-title":"J Pharm Biomed Anal"},{"key":"154_CR51","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.forsciint.2008.08.012","volume":"182","author":"T Nakamae","year":"2008","unstructured":"Nakamae T, Shinozuka T, Sasaki C, Ogamo A, Murakami-Hashimoto C, Irie W, Terada M, Nakamura S, Furukawa M, Kurihara K (2008) Case report: etizolam and its major metabolites in two unnatural death cases. Forensic Sci Int 182:e1\u2013e6","journal-title":"Forensic Sci Int"},{"key":"154_CR52","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/dta.2146","volume":"9","author":"C Noble","year":"2017","unstructured":"Noble C, Mardal M, Bjerre Holm N, Stybe Johansen S, Linnet K (2017) In vitro studies on flubromazolam metabolism and detection of its metabolites in authentic forensic samples. Drug Test Anal 9:1182\u20131191","journal-title":"Drug Test Anal"},{"key":"154_CR53","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/jat\/bkv122","volume":"40","author":"LC O\u2019Connor","year":"2015","unstructured":"O\u2019Connor LC, Torrance HJ, McKeown DA (2015) ELISA detection of phenazepam, etizolam, pyrazolam, flubromazepam, diclazepam and delorazepam in blood using Immunalysis\u00ae Benzodiazepine Kit. J Anal Toxicol 40:159\u2013161","journal-title":"J Anal Toxicol"},{"key":"154_CR54","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1124\/pr.108.00505","volume":"60","author":"RW Olsen","year":"2008","unstructured":"Olsen RW, Sieghart W (2008) International Union of Pharmacology. LXX. Subtypes of \u03b3-aminobutyric acidA receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol Rev 60:243\u2013260","journal-title":"Pharmacol Rev"},{"key":"154_CR55","first-page":"S59","volume":"29","author":"R Peter","year":"2017","unstructured":"Peter R, Wicht A, Moosmann B, Huppertz L-M, Kempf J, Joly R (2017) Semi-quantitative determination of designer benzodiazepines in serum by adaption of an automated LC-MSn screening approach. Toxicol Anal Clin 29:S59\u2013S60","journal-title":"Toxicol Anal Clin"},{"key":"154_CR56","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jchromb.2016.08.047","volume":"1035","author":"M Pettersson Bergstrand","year":"2016","unstructured":"Pettersson Bergstrand M, Helander A, Beck O (2016) Development and application of a multi-component LC-MS\/MS method for determination of designer benzodiazepines in urine. J Chromatogr B Analyt Technol Biomed Life Sci 1035:104\u2013110","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"154_CR57","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/dta.2003","volume":"9","author":"M Pettersson Bergstrand","year":"2017","unstructured":"Pettersson Bergstrand M, Helander A, Hansson T, Beck O (2017a) Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays. Drug Test Anal 9:640\u2013645","journal-title":"Drug Test Anal"},{"issue":"3","key":"154_CR58","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/dta.2243","volume":"10","author":"Madeleine Pettersson Bergstrand","year":"2017","unstructured":"Pettersson Bergstrand M, Meyer MR, Beck O, Helander A (2017b) Human urinary metabolic patterns of the designer benzodiazepines flubromazolam and pyrazolam studied by liquid chromatography-high resolution mass spectrometry. Drug Test Anal. https:\/\/doi.org\/10.1002\/dta.2243","journal-title":"Drug Testing and Analysis"},{"key":"154_CR59","first-page":"91","volume":"82","author":"W Rudolph","year":"2015","unstructured":"Rudolph W, Remane D, Moosmann B, Lemke S, Auw\u00e4rter V, Peters FT (2015) First reported intoxication involving the four designer benzodiazepines, flubromazepam, diclazepam, pyrazolam, and etizolam. Toxichem Krimtech 82:91","journal-title":"Toxichem Krimtech"},{"key":"154_CR60","first-page":"88","volume":"49","author":"E Sanna","year":"1999","unstructured":"Sanna E, Pau D, Tuveri F, Massa F, Maciocco E, Acquas C, Floris C, Fontana SN, Maira G, Biggio G (1999) Molecular and neurochemical evaluation of the effects of etizolam on GABAA receptors under normal and stress conditions. Arzneimittelforschung 49:88\u201395","journal-title":"Arzneimittelforschung"},{"key":"154_CR61","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0022-3565(25)27131-2","volume":"149","author":"MA Schwartz","year":"1965","unstructured":"Schwartz MA, Koechlin BA, Postma E, Palmer S, Krol G (1965) Metabolism of diazepam in rat, dog, and man. J Pharmacol Exp Ther 149:423\u2013435","journal-title":"J Pharmacol Exp Ther"},{"key":"154_CR62","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/anie.197100341","volume":"10","author":"LH Sternbach","year":"1971","unstructured":"Sternbach LH (1971) 1,4-Benzodiazepines. Chemistry and some aspects of the structure-activity relationship. Angew Chem Int Ed 10:34\u201343","journal-title":"Angew Chem Int Ed"},{"key":"154_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1021\/jm00187a001","volume":"22","author":"LH Sternbach","year":"1979","unstructured":"Sternbach LH (1979) The benzodiazepine story. J Med Chem 22:1\u20137","journal-title":"J Med Chem"},{"key":"154_CR64","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1021\/jo01058a010","volume":"27","author":"LH Sternbach","year":"1962","unstructured":"Sternbach LH, Fryer RI, Metlesics W, Reeder E, Sach G, Saucy G, Stempel A (1962a) Quinazolines and 1,4-benzodiazepines. VI.1a halo-, methyl-, and methoxy-substituted 1,3-Dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones1b,c. J Org Chem 27:3788\u20133796","journal-title":"J Org Chem"},{"key":"154_CR65","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1021\/jo01058a009","volume":"27","author":"LH Sternbach","year":"1962","unstructured":"Sternbach LH, Fryer RI, Metlesics W, Sach G, Stempel A (1962b) Quinazolines and 1,4-benzodiazepines. V. o-aminobenzophenones1a,b. J Org Chem 27:3781\u20133788","journal-title":"J Org Chem"},{"key":"154_CR66","volume-title":"Drugs affecting the central nervous system","author":"LH Sternbach","year":"1968","unstructured":"Sternbach LH, Randall LO, Banziger R, Lehr H (1968) Structure-activity relationships in the 1,4-benzodiazepine series. In: Burger A (ed) Drugs affecting the central nervous system, vol 2. Edward Arnold, London"},{"key":"154_CR67","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.talanta.2017.08.010","volume":"176","author":"M \u0160vidrnoch","year":"2018","unstructured":"\u0160vidrnoch M, Bor\u00e1\u0148ov\u00e1 B, Tomkov\u00e1 J, Ondra P, Maier V (2018) Simultaneous determination of designer benzodiazepines in human serum using non-aqueous capillary electrophoresis \u2013 tandem mass spectrometry with successive multiple ionic \u2013 polymer layer coated capillary. Talanta 176:69\u201376","journal-title":"Talanta"},{"key":"154_CR68","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1002\/jssc.201700069","volume":"40","author":"J Tomkova","year":"2017","unstructured":"Tomkova J, Svidrnoch M, Maier V, Ondra P (2017) Analysis of selected designer benzodiazepines by ultra high performance liquid chromatography with high-resolution time-of-flight mass spectrometry and the estimation of their partition coefficients by micellar electrokinetic chromatography. J Sep Sci 40:2037\u20132044","journal-title":"J Sep Sci"},{"key":"154_CR69","unstructured":"Tripsit (2018.) https:\/\/tripsit.me\/ . Accessed 1 Feb 2018"},{"key":"154_CR70","unstructured":"UNODC (1997) Recommended methods for the detection and assay of barbiturates and benzodiazepines in biological specimens. Manual for use by National Laboratories. UN document ID number: ST\/NAR\/28 edn. United Nations Office on Drugs and Crime, New York"},{"key":"154_CR71","unstructured":"UNODC (2018) Thirty-seventh meeting of the Expert Committee on Drug Dependence. http:\/\/www.who.int\/medicines\/access\/controlled-substances\/ecdd_37_meeting\/en\/ . Accessed 1 Feb 2018"},{"key":"154_CR72","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1208\/s12248-016-0040-x","volume":"19","author":"S Vikingsson","year":"2017","unstructured":"Vikingsson S, Wohlfarth A, Andersson M, Green H, Roman M, Josefsson M, Kugelberg FC, Kronstrand R (2017) Identifying metabolites of meclonazepam by high-resolution mass spectrometry using human liver microsomes, hepatocytes, a mouse model, and authentic urine samples. AAPS J 19:736\u2013742","journal-title":"AAPS J"},{"issue":"3","key":"154_CR73","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.scijus.2017.12.004","volume":"58","author":"Laura Waters","year":"2018","unstructured":"Waters L, Manchester KR, Maskell PD, Haider S, Haegeman C (2017) The use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepines. Sci Justice. https:\/\/doi.org\/10.1016\/j.scijus.2017.12.004","journal-title":"Science & Justice"},{"key":"154_CR74","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.forsciint.2016.10.021","volume":"274","author":"A Wohlfarth","year":"2017","unstructured":"Wohlfarth A, Vikingsson S, Roman M, Andersson M, Kugelberg FC, Green H, Kronstrand R (2017) Looking at flubromazolam metabolism from four different angles: metabolite profiling in human liver microsomes, human hepatocytes, mice and authentic human urine samples with liquid chromatography high-resolution mass spectrometry. Forensic Sci Int 274:55\u201363","journal-title":"Forensic Sci Int"},{"key":"154_CR75","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/BF03189565","volume":"7","author":"VP Zherdev","year":"1982","unstructured":"Zherdev VP, Caccia S, Garattini S, Ekonomov AL (1982) Species differences in phenazepam kinetics and metabolism. Eur J Drug Metab Pharmacokinet 7:191\u2013196","journal-title":"Eur J Drug Metab Pharmacokinet"}],"container-title":["Handbook of Experimental Pharmacology","New Psychoactive Substances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2018_154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T21:58:36Z","timestamp":1775253516000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/164_2018_154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9783030105600","9783030105617"],"references-count":75,"URL":"https:\/\/doi.org\/10.1007\/164_2018_154","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]},"assertion":[{"value":"27 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}